AMRX - Amneal Pharmaceuticals Non-GAAP EPS of $0.23 beats by $0.02 revenue of $610M beats by $30.07M
- Amneal Pharmaceuticals press release ( NYSE: AMRX ): Q4 Non-GAAP EPS of $0.23 beats by $0.02 .
- Revenue of $610M (+13.6% Y/Y) beats by $30.07M .
- FY2023 Outlook : Net revenue of $2.25B to $2.35B vs. consensus of $2.31B and Adjusted diluted EPS of $0.40 to $0.50 vs. consensus of $0.77.
- Shares +6.7% PM.
For further details see:
Amneal Pharmaceuticals Non-GAAP EPS of $0.23 beats by $0.02, revenue of $610M beats by $30.07M